Seed round · Phoenix, AZ

The neutral connective infrastructure for compounded medicine.

PEPTPlus connects prescribers to vetted compounding pharmacies, neutrally. Rules-based matching, NCPDP SCRIPT e-prescribing, and end-to-end fulfillment tracking, on flat subscriptions with $0 tied to the drug. A live platform, ready to transact today.

Why now
$6.45B → $11.5B
U.S. compounding pharmacy market, by 2035
1,400+
FDA adverse-event reports on compounded GLP-1s
216 to 223
active U.S. drug shortages pushing toward compounding
~8.7 hrs/wk
physician time lost to administrative work

A booming market with no map

Compounded medicine is surging, driven by persistent drug shortages, the GLP-1 / peptide boom, and personalized care. Yet thousands of compounding pharmacies have no shared directory and no neutral way to be found or compared, while a wave of quality scrutiny makes verification table stakes. The cost: delayed therapies, inconsistent access, and the best-suited pharmacy never reached.

We replace guesswork with infrastructure

PEPTPlus brings vetted compounding pharmacies into one connected network and matches each patient to the right pharmacy, neutrally. Flat subscription pricing, no per-prescription cut, no share of drug cost. We never profit from steering a script, which is precisely what makes both sides trust the rails.

One connected workflow

A single workflow serving prescribers and pharmacies alike.

1

Discover

Vetted compounding pharmacies in one place, not word of mouth.

2

Match

A neutral, rules-based engine pairs each patient to a fit pharmacy. No pay-to-play.

3

e-Prescribe

Transmit electronically via the industry-standard NCPDP SCRIPT format.

4

Track

Follow fulfillment in one place; the pharmacy stays pharmacy of record.

Neutral by design

Revenue is decoupled from prescription volume and drug cost; ARR grows with seats, not drug spend. Neutrality isn't just a value; it's the business model, and the foundation of a defensible, two-sided network. The full defensibility thesis lives in the data room.

No per-prescription cutNo share of drug costRules-based, auditable matchingTwo-sided network effects

Live platform. Real workflow.

  • Platform in production: prescriber, pharmacy, lab & admin experiences built end-to-end
  • NCPDP SCRIPT e-prescribing and the neutral matching engine, live
  • Flat-fee, neutral revenue model in place: $0 tied to the drug
  • Ready for prescribers and pharmacies to transact today

Why now

  • Demand is here today; the neutral infrastructure to serve it safely is not here yet
  • Quality scrutiny makes verification & traceability table stakes
  • First-mover on the neutral position, before the category consolidates
  • An 18-month plan to turn on the two-sided flywheel (detailed in the data room)

Founders, board & advisors

Operators at the intersection of healthcare and software, building the trusted, neutral rails for compounded medicine.

Founders & Board
AA
Andre Alex
Co-Founder & CEO · Board

Healthcare-marketplace and digital-health operator. Leads vision, fundraising, and pharmacy partnerships.

TS
Trey Smith
Co-Founder & CTO · Board

Health-tech engineering leader. Built our NCPDP SCRIPT e-prescribing and the neutral matching engine.

·
Independent Director
Board

An independent director with healthcare and pharmacy-operations experience is being added to the board.

Appointment pending
Board of Advisors
Rx
Clinical & Regulatory
Advisor

Pharmacy (503A / 503B) and compliance expertise; guides verification standards and quality.

Appointment pending
Ops
Pharmacy Operations
Advisor

Compounding-pharmacy operations and quality leadership across 503A / 503B networks.

Appointment pending
GTM
Growth & Go-to-Market
Advisor

Scaling two-sided healthcare marketplaces and prescriber adoption.

Appointment pending

What's in the data room

We keep the numbers where they belong: with qualified, accredited investors. Request access and we'll share:

Financial model & projections

Bottom-up ARR build, margins, and the path to a self-sustaining network.

Market & opportunity

TAM / SAM / SOM, the beachhead strategy, and the 18-month go-to-market plan.

Moat & round terms

The defensibility thesis, traction detail, the raise, valuation, and use of funds.

Interested in investing?

Accredited investors only. Submit the form and our team will follow up with the data room: the financial model, market sizing, the moat thesis, and the round terms.

Accredited investor requirements: You must meet the SEC requirements for accredited-investor status and understand the minimum investment is $10,000.